Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

Raymond James Downgrades First Commonwealth to Market Perform

July 7, 7:48 AM

Raymond James analyst David Feaster downgrades First Commonwealth (NYSE:FCF) from Outperform to Market Perform.

February 12, 4:00 PM

4 analysts have expressed a variety of opinions on WEX (NYSE:WEX) over the past quarter, offering a diverse…

August 4, 4:50 PM

"Diversity is profitable. Black people buy weed. Brown people buy weed. We are selling weed.

January 12, 4:48 PM

https://www.ft.com/content/74fc28b8-0499-406e-95d1-a7b99f5e52e9 Warner Bros Discovery weighs sale of music library to pare debt